A new universal analgesic

TSU helped to create an effective analgesic without side effects

TSU Press Service

Scientists of the Institute of Problems of Chemical and Energy Technologies SB RAS (Biysk), with the participation of colleagues from TSU, have developed thiovurcin, a universal drug for the treatment of pain of various origins. The feature of the new analgesic is the absence of side effects characteristic of steroid and nonsteroidal anti-inflammatory drugs.

– Glyoxal is used as a raw material for a new drug, a substance whose industrial synthesis technology was developed by chemists of Tomsk State University, – says Sergey Sysolyatin, Director of IPHET SB RAS (graduate of the TSU HF). – High-energy compounds are also produced on the basis of glyoxal. At the intermediate stage of synthesis, we withdraw a small part of the substance, refine it and obtain a drug with excellent pharmacological characteristics.

Preclinical tests conducted on the basis of the E.D. Goldberg Institute of Pharmacology and Regenerative Medicine (Tomsk) showed that the new analgesic relieves pain syndromes of various etiologies, has a longer period of action than other painkillers, but at the same time does not have a toxic effect on the body. According to experts, thiovurcin meets the requirements of hazard class IV – "low-hazard substances". The degree of its toxic effects on the body is comparable in severity except with overeating.

In addition, with prolonged administration of the drug (28 days), drug dependence does not develop, breathing does not suffer, there is no stimulating effect on the central nervous system, which indicates the absence of a morphine-like effect of the drug.

– I think that the new technology of Biysk Institute is a big step forward for modern pharmacology, – says TSU professor, deputy director of IPHET SB RAS, director of TP "Medicine of the Future" Alexander Vorozhtsov. – Previously, the use of glyoxal as a raw material for the synthesis of hexaazoisovurcitan was mainly defensive in nature. Only in recent years, such chemical compounds have begun to be considered from the point of view of their application in medicine.

This issue is discussed in the scientific and medical literature, but only Russian scientists have priority publications on this topic, and now practical developments.

We should add that preclinical trials of the new drug are in the final stage. A patent has already been obtained for this development. A joint project of Biysk and Tomsk scientists is planned to be implemented within the framework of the Federal Target Program "Development of the pharmaceutical and medical industry of the Russian Federation for the period up to 2020 and beyond".

Portal "Eternal youth" http://vechnayamolodost.ru  23.09.2016